Misyo (Methadone Hydrochloride)

Methadone Hydrochloride acts on the opioid system and is indicated for several established therapeutic areas.

• Opioid dependence: provides maintenance therapy to reduce illicit opioid use and support abstinence.
• Chronic pain: delivers long‑acting analgesia for patients requiring continuous opioid control.
• Opioid withdrawal: suppresses withdrawal symptoms during detoxification phases.

• Methadone Hydrochloride is a full agonist at the mu‑opioid receptor, binding with high affinity to activate the receptor and produce analgesia while also attenuating the neurochemical changes that underlie opioid withdrawal. Its long half‑life provides sustained receptor occupancy, allowing once‑daily dosing in maintenance programs and continuous pain relief.

Methadone Hydrochloride may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Constipation: reduced bowel motility leading to hard stools.
• Nausea: feeling of queasiness, sometimes with vomiting.
• Drowsiness: increased sleepiness or fatigue.
• Sweating: excessive perspiration, especially during dose adjustments.
• Dry mouth: reduced salivation causing throat discomfort.
• Dizziness: light‑headed sensation, particularly on standing.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be life‑threatening.
• QT interval prolongation: cardiac rhythm disturbance that may cause arrhythmia.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Adrenal insufficiency: inadequate cortisol production causing fatigue and weakness.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Seizures: rare occurrence of convulsive episodes.

When prescribing Methadone Hydrochloride, clinicians should observe several safety measures.

• Assess respiratory function: monitor breathing, especially in opioid‑naïve patients.
• Monitor cardiac conduction: obtain baseline ECG and watch for QT prolongation.
• Evaluate liver function: adjust dosing in hepatic impairment.
• Use caution in the elderly: start with lower doses to reduce overdose risk.
• Avoid abrupt discontinuation: taper gradually to prevent withdrawal.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Methadone Hydrochloride interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression.
• MAO inhibitors: can precipitate hypertensive crisis or serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase methadone plasma levels, raising toxicity risk.
• QT‑prolonging agents (e.g., quinidine, sotalol): amplify cardiac rhythm disturbances.
• Potent CYP2B6 inducers (e.g., rifampin): may reduce methadone effectiveness.

Moderate Interactions (Monitor Closely)

• SSRIs and SNRIs: may enhance serotonergic effects.
• Alcohol: additive CNS depression.
• Other opioids: cumulative opioid effect.
• Antihistamines with sedative properties: increase drowsiness.
• Anticonvulsants (e.g., carbamazepine): may modestly lower methadone levels.